Arnaud Foussat

Company: Carmil Therapeutics

Job title: Chief Executive Officer

Bio:

Dr. Arnaud Foussat, Chief Executive Officer, brings 20 years of experience in immunotherapy development and biotech management to Carmil Therapeutics. Previously, Arnaud was Chief Scientific Officer at TxCell (acquired by Sangamo Therapeutics in 2018), where he developed the first generation of cell therapy products using Treg cells and launched the first program on CAR-engineered Treg cells.

Seminars:

Engineering Co-Stimulation-Independent T-Cells to Overcome Tumor Immunosuppression 11:00 am

Introducing a gain-of-function gene that enhances T-Cell sensitivity to low antigen levels and bypasses CD28 costimulation Demonstrating resistance to PD-1 and CTLA-4 mediated suppression, improving efficacy in low-immunogenic tumors Exploring translational potential for TIL therapies beyond melanoma through strategic partnershipsRead more

day: Conference Day One R&D Track AM